The University Of Western Ontario, offers professional courses for both graduate and under-graduate students. The University Of Western Ontario was founded in 1878 and is based in London, Ontario.
1151 Richmond Street
London, ON N6A 5B8
Founded in 1878
The University Of Western Ontario Presents at British Pharmacological Meeting 2017, Dec-11-2017 through Dec-13-2017
Dec 8 17
The University Of Western Ontario Presents at British Pharmacological Meeting 2017, Dec-11-2017 through Dec-13-2017. Venue: Queen Elizabeth II Conference Centre, Broad Sanctuary, Westminster, London, United Kingdom. Presentation Date & Speakers: Dec-12-2017, Michael Rieder.
The University of Western Ontario Presents at 2017 World Congress on Industrial Biotechnology, Jul-23-2017
Jul 20 17
The University of Western Ontario Presents at 2017 World Congress on Industrial Biotechnology, Jul-23-2017 . Venue: Palais des congrès de Montréal, Montréal, Quebec, Canada. Speakers: Reyna Gomez-Flores, Doctorate Student.
Algae Dynamics Corp Announces Research Agreement with University of Western Ontario to Investigate the Use of Cannabis Derivatives
Mar 13 17
Algae Dynamics Corp. announced a research and product development agreement with Western University to perform research on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia. This is the second of the recently announced research agreements with Canadian universities involving cannabis oil research. This announcement brings Algae Dynamics total university research contributions to $1.6 million for both programs. This research agreement will directly support this initiative and will focus on translational pharmaceutical research, with a specific focus on identifying how specific phytochemical compounds found in cannabis, including delta-9-tetrahydrocannbinol (THC), cannabidiol (CBD), cannabinoid-derived terpenoids and other potential phytochemical derivatives of cannabis may serve as novel pharmacological treatments for symptoms associated with depression, post-traumatic stress disorder, anxiety and schizophrenia. The Company's contribution to the four-year Sponsored Research Agreement, which commences April 1, 2017 and terminates March 30, 2021, is CAD 250,000 per year. The Company believes, from past experience, that it will be able to leverage the research expenditures with matching scientific grants pursuant to programs of various branches of government. The Company will be responsible for the filing of patents relating to this research and will own such patents if and when issued. The Company has agreed to make payments to the University upon filing of each patent, when each patent is issued, after first commercial sale and when gross sales reach CAD 1,000,000. There are no ongoing royalty payments, relating to the use of the patents. The work plan may be extended and modified to achieve best outcomes which may include delegating specific research areas of research work that require additional technologies to appropriate providers; and engaging research collaborators to extend the research into additional areas of benefit to the Company. The Company's core product development strategy has been the production of high volume specific algae species and extraction of Essential Fatty Acids (EFAs) which is the foundation of the endocannabinoid system (ECS). The ECS is a group of endogenous cannabinoid receptors located in the mammalian brain and throughout the central and peripheral nervous systems, consisting of neuromodulatory lipids and their receptors. The extracted algae Omega 3 oil with high concentrations of DHA is used as a health supplement product. In light of the potential synergies, the company has developed its strategy which is aimed at developing new products and formulations that combine the health benefits of algae and cannabis oils.